
The 5th International Neuroscience Summit for the Middle East, Africa and Russia is being held in Dubai
Saudi Arabia - The International Neurology Conference for the Middle East, Africa and Russia kicked off in Dubai, in cooperation with AbbVie, the global biopharmaceutical research and development company, with the participation of an elite group of international and national speakers and in the presence of several consultants, specialist physicians, researchers, professors and neurology experts from Gulf countries, Saudi Arabia, Egypt and Russia, in addition to several international, regional and local medical associations. The conference included several scientific lectures that discuss the latest research and treatment methods for many neurological diseases such as Parkinson's disease, migraine and post-stroke spasticity.
Dr. Abdulrazzaq Al-Bilali, Headache Specialist and Head of the Saudi Headache Chapter, Saudi Neurology Society, commended the continuous efforts of the organizers of this major conference and its success for the fifth consecutive year. Dr. Abdulrazzaq emphasized that scientific research is the cornerstone of progress in the field of neurology. He explained that headache is a health problem that significantly impacts people's lives and daily activities, and that significant developments have occurred in diagnostic methods and disease management. He emphasized that the future of patient care lies in innovation and evidence-based knowledge.
For his part, Dr. Suhail Al Rukun, consultant neurology, President of Emirates neurology Society in the United Arab Emirates, praised the large turnout at the conference, which included valuable medical discussions, workshops, and a review of the latest recommendations from clinical trials and research in this sector, in addition to presenting the best methods used in the management of patients with neurological diseases. Dr. Suhail added that this prominent scientific event is a good opportunity to exchange experiences and keep up with the latest developments in the neurology field. Organizing this summit for the fifth consecutive year embodies the ongoing commitment to enhancing medical knowledge and achieving the best treatment outcomes for patients. These initiatives help improve the quality of healthcare and open new horizons for improving patients' lives.
Mohammad Aboubakr, Vice President and General Manager of AbbVie's Middle East, Africa & Russia region, commended the launch of the fifth Neurology Summit, which highlighted the latest emerging scientific and medical developments. He emphasized that organizing the summit reflects AbbVie's commitment to enhancing scientific training and research programs and providing a high level of medical care to serve society members by providing what helps improve their quality of life. The company seeks to help make a real difference in patients' lives, as well as its commitment to raising awareness and health education for patients, and on the other hand, its focus on the fields of education, training and scientific research.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The National
7 hours ago
- The National
Israel continues Gaza attacks with 57 reported killed
Israeli strikes in Gaza have killed at least 57 people in the past day, health officials said on Sunday, as Israel continues to attack the strip despite its continuing conflict with Iran. Gaza's Health Ministry said the latest deaths took the total to at least 5,071 since Israel resumed its operations in mid-March, ending a two-month ceasefire. Eight more bodies of people killed in earlier attacks were also recovered. At least five people were killed on Sunday near aid sites operated by the US-backed Gaza Humanitarian Foundation, according to health authorities. Medics at Al Awda Hospital in central Gaza said at least three people were killed and dozens wounded by Israeli fire as they tried to approach a GHF site near the Netzarim corridor. Two others were reported killed en route to another aid site in Rafah in the south. A separate air strike killed seven people in Beit Lahia in northern Gaza, medics said. There was no immediate comment from the Israeli military. The GHF began distributing food packages in Gaza at the end of May after Israel partially lifted a near three-month total blockade. Scores of Palestinians have been killed in near-daily shootings trying to reach the food. The UN rejects the Israeli-backed distribution system as inadequate, dangerous, and a violation of humanitarian principles. The Israeli army meanwhile said on Sunday that a soldier had been killed in battle in Gaza a day earlier, as its war with Hamas enters its 20th month. The army said Noam Shemesh, 21, from Jerusalem, "fell during combat" in the south of Gaza. About 430 soldiers have been killed since Israel's ground operation in Gaza began in late October 2023. The war in Gaza erupted 20 months ago after Hamas-led militants raided Israel, took 251 hostages and killed 1,200 people, most of them civilians, on October 7, 2023, Israel's single deadliest day. Israel's military campaign since has killed more than 55,362 Palestinians, most of them civilians, according to health authorities in Gaza, and flattened much of the densely populated strip, which is home to more than two million people. Most of the population is displaced, and malnutrition is widespread. Despite efforts by the United States, Egypt, and Qatar to restore a ceasefire in Gaza, neither Israel nor Hamas has shown willingness to back down on core demands, with each side blaming the other for the failure to reach a deal.


Zawya
8 hours ago
- Zawya
The 5th International Neuroscience Summit for the Middle East, Africa and Russia is being held in Dubai
Saudi Arabia - The International Neurology Conference for the Middle East, Africa and Russia kicked off in Dubai, in cooperation with AbbVie, the global biopharmaceutical research and development company, with the participation of an elite group of international and national speakers and in the presence of several consultants, specialist physicians, researchers, professors and neurology experts from Gulf countries, Saudi Arabia, Egypt and Russia, in addition to several international, regional and local medical associations. The conference included several scientific lectures that discuss the latest research and treatment methods for many neurological diseases such as Parkinson's disease, migraine and post-stroke spasticity. Dr. Abdulrazzaq Al-Bilali, Headache Specialist and Head of the Saudi Headache Chapter, Saudi Neurology Society, commended the continuous efforts of the organizers of this major conference and its success for the fifth consecutive year. Dr. Abdulrazzaq emphasized that scientific research is the cornerstone of progress in the field of neurology. He explained that headache is a health problem that significantly impacts people's lives and daily activities, and that significant developments have occurred in diagnostic methods and disease management. He emphasized that the future of patient care lies in innovation and evidence-based knowledge. For his part, Dr. Suhail Al Rukun, consultant neurology, President of Emirates neurology Society in the United Arab Emirates, praised the large turnout at the conference, which included valuable medical discussions, workshops, and a review of the latest recommendations from clinical trials and research in this sector, in addition to presenting the best methods used in the management of patients with neurological diseases. Dr. Suhail added that this prominent scientific event is a good opportunity to exchange experiences and keep up with the latest developments in the neurology field. Organizing this summit for the fifth consecutive year embodies the ongoing commitment to enhancing medical knowledge and achieving the best treatment outcomes for patients. These initiatives help improve the quality of healthcare and open new horizons for improving patients' lives. Mohammad Aboubakr, Vice President and General Manager of AbbVie's Middle East, Africa & Russia region, commended the launch of the fifth Neurology Summit, which highlighted the latest emerging scientific and medical developments. He emphasized that organizing the summit reflects AbbVie's commitment to enhancing scientific training and research programs and providing a high level of medical care to serve society members by providing what helps improve their quality of life. The company seeks to help make a real difference in patients' lives, as well as its commitment to raising awareness and health education for patients, and on the other hand, its focus on the fields of education, training and scientific research. About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.


Zawya
8 hours ago
- Zawya
Abu Dhabi reinforces global leadership in healthcare innovation with high-level U.S. visit
Abu Dhabi, United Arab Emirates – A high-level delegation led by the Department of Health – Abu Dhabi (DoH), is set to embark on a strategic mission to the United States from June 14 to 21, 2025. The visit reaffirms Abu Dhabi's global leadership in healthcare innovation and reflects its broader vision for healthcare transformation—driven by innovation, investment, and a deep commitment to global collaboration. The delegation will visit key U.S. cities including Boston, Washington D.C., and Philadelphia, in parallel with Abu Dhabi's participation at BIO International Convention 2025, one of the world's foremost biotechnology events. The visit will spotlight the Emirate's achievements in AI, digital health, genomics, and clinical research and showcase Abu Dhabi's Health, Endurance, Longevity and Medicine (HELM) Life Science Cluster, while promoting long-term strategic partnerships with government entities, research institutions, and global innovators. H.E. Dr. Noura Khamis Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi, stated: 'This mission reflects our commitment to shaping the future of health through collaboration, innovation, and shared purpose. Our vision is to build a health system that predicts, prevents, acts to restore, and acts to cure, therefore ensuring better outcomes for our communities and beyond. This can only be achieved through meaningful partnerships and a shared ambition to improve lives. We are proud to join our partners in the United States to explore new opportunities that advance healthcare, both in the UAE and globally.' The delegation will conduct over 20 strategic meetings and visits with public and private sector leaders across the U.S., aimed at knowledge exchange, investment opportunities, and the signing of new agreements that accelerate the adoption of advanced health solutions. Representing Abu Dhabi's innovation ecosystem, the delegation includes key stakeholders such as the Abu Dhabi Investment Office, Mubadala BIO, M42, Masdar City, KEZAD, PureHealth, and Etihad Cargo. Abu Dhabi continues to lead the region in genomics through the Emirati Genome Programme, which has successfully sequenced over 800,000 samples, creating one of the most advanced national genomic databases. The Emirate is also home to more than 90 licensed research centers and 30+ ongoing clinical trials in areas such as oncology, rare diseases, and chronic conditions. Advanced data platforms such as Malaffi, which securely store over 5 million patient records—enable AI-powered insights and real-world evidence, while national initiatives like the Golden Visa program are cultivating a global workforce and have granted over 2,000 long-term visas for researchers and healthcare professionals from around the world. About the Department of Health – Abu Dhabi (DoH): The Department of Health – Abu Dhabi is the regulative body of the healthcare sector in the Emirate of Abu Dhabi. Committed to ensuring excellence in healthcare, DoH monitors the health status of the population while shaping the regulatory framework for the health system. This includes inspecting against regulations, enforcing standards and encouraging the adoption of world-class best practices and performance targets by all healthcare providers in the Emirate. Abu Dhabi remains dedicated to shaping the future of healthcare by establishing an intelligent and sustainable ecosystem that prioritises health, longevity and quality of life for all community members. Leveraging state-of-the-art infrastructure and cutting-edge capabilities, DoH continues to develop and implement initiatives and programmes in line with its strategic focus areas, Healthy Population, Best-in-Class Care and Resilience and Innovation. These efforts reflect DoH's unwavering commitment to predicting, preventing and personalising healthcare for every individual. For further information on DOH, visit and follow on X, Instagram, Facebook, LinkedIn and YouTube. For media inquiries, please contact: Mariam Al Marzooqi, msalmarzooqi@